Kymab raises US$40 million in Series B financing

Kymab, a monoclonal antibody biopharmaceutical company, announced today it has successfully raised US$40 million in a Series B financing. The Bill & Melinda Gates Foundation joins existing investor, the Wellcome Trust, each investing US$20 million.  

The funds will enable Kymab to maximise the potential of its Kymouse™ platform and advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies in areas of significant unmet medical need.  Kymab will also collaborate with the Gates Foundation and its partners on vaccine antigen discovery research and development with an initial focus on malaria and HIV.

Dr Christian Grøndahl, Chief Executive Officer of Kymab, said:  "We are delighted to attract investment from two of the world's largest foundations. This is a strong financial and scientific endorsement of Kymab as we advance our proprietary pipeline of first-in-class therapeutics in areas of significant unmet medical need, including cancer and inflammation." 

Dr David Chiswell, Chairman of Kymab, added:  "Kymab's highly innovative and technically advanced Kymouse™ platform has overcome the problems which limited previous generations of human antibody-generating mice. This increased financial strength and addition of new long term investors gives the Company a strong foundation on which we can build a global biotechnology company." 

Dr Richard Davis, at the Investments Division of the Wellcome Trust and Board Director of Kymab added:  "Syndicating this Series B financing with a like-minded, long term investor such as the Gates Foundation signals our collective intention to support Kymab and its management team in realising its full potential as a sustainable and successful biotechnology company." 

Dr. Trevor Mundel, President of Global Health, at the Bill & Melinda Gates Foundation commented:  "We are excited to work with Kymab in pursuit of research and development of drugs and vaccines to address diseases that have a disproportionate impact on the world's poorest.  We believe Kymab has one of the most comprehensive transgenic technologies to date, capturing the entire human IgG diversity and are pleased to support the Company as it enters its next stage of growth." 

Kymab is using the Kymouse™ transgenic human antibody platform to discover and develop fully human monoclonal antibody drugs. Recent data published in Nature Biotechnology demonstrate that the Kymouse™ technology yields an antibody library constituted from 100 trillion different antibodies.  From this deep library rare high-quality antibodies can be selected and developed into therapeutics.  

Antibodies are one of the best-selling classes of drugs today; five of the top ten best selling drugs are antibodies. This is because antibodies are natural products with exquisite specificity and potency, and generally have superior safety profiles. The challenge has been to capture the full human antibody repertoire and to recapitulate all its attributes.

To complement the growth of its internal pipeline of programmes, Kymab will seek to enter into a limited number of strategic collaborations to identify and develop therapeutic antibodies in a range of diseases. In addition, Kymab has established Kymab Access, a programme that enables academic researchers to pursue the discovery and development of novel human monoclonal antibody therapeutics and vaccines by partnering with Kymab and its world leading Kymouse™ antibody technology.





The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Global resurgence of whooping cough can be attributed to immunological failures of vaccines